**ANNEX I**

**SUMMARY OF PRODUCT CHARACTERISTICS**

**1. NAME OF THE MEDICINAL PRODUCT**

Temozolomide SUN 5 mg hard capsules

Temozolomide SUN 20 mg hard capsules

Temozolomide SUN 100 mg hard capsules

Temozolomide SUN 140 mg hard capsules

Temozolomide SUN 180 mg hard capsules

Temozolomide SUN 250 mg hard capsules

**2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

5 mg hard capsules

Each hard capsule contains 5 mg temozolomide.

Excipient with known effect

Each hard capsule contains 30.97 mg of lactose.

20 mg hard capsules

Each hard capsule contains 20 mg temozolomide.

Excipient with known effect

Each hard capsule contains 18.16 mg of lactose.

100 mg hard capsules

Each hard capsule contains 100 mg temozolomide.

Excipient with known effect

Each hard capsule contains 90.801 mg of lactose.

140 mg hard capsules

Each hard capsule contains 140 mg temozolomide.

Excipient with known effect

Each hard capsule contains 127.121 mg of lactose.

180 mg hard capsules

Each hard capsule contains 180 mg temozolomide.

Excipient with known effect

Each hard capsule contains 163.441 mg of lactose.

250 mg hard capsules

Each hard capsule contains 250 mg temozolomide.

Excipient with known effect

Each hard capsule contains 227.001 mg of lactose.

For the full list of excipients, see section 6.1.

**3. PHARMACEUTICAL FORM**

5 mg hard capsule (capsule)

Hard gelatin capsules, with white opaque cap and body, imprinted in green ink. The cap is imprinted with ‘890’. The body is imprinted with ‘5 mg’ and two stripes.

20 mg hard capsule (capsule)

Hard gelatin capsules, with white opaque cap and body, imprinted in yellow ink. The cap is imprinted with ‘891’. The body is imprinted with ’20 mg’ and two stripes.

100 mg hard capsule (capsule)

Hard gelatin capsules, with white opaque cap and body, imprinted in pink ink. Thw cap is imprinted with ‘892’. The body is imprinted with ‘100 mg’ and two stripes.

140 mg hard capsule (capsule)

Hard gelatin capsules, with white opaque cap and body, imprinted in blue ink. The cap is imprinted with ‘929’. The body is imprinted with ‘140 mg’ and two stripes.

180 mg hard capsule (capsule)

Hard gelatin capsules, with white opaque cap and body, imprinted in red ink. The cap is imprinted with ‘930’. The body is imprinted with ‘180 mg’ and two stripes.

250 mg hard capsule (capsule)

Hard gelatin capsules, with white opaque cap and body, imprinted in black ink. The cap is imprinted with ‘893’. The body is imprinted with ‘250 mg’ and two stripes.

**4. CLINICAL PARTICULARS**

**4.1 Therapeutic indications**

Temozolomide SUN is indicated for the treatment of:

* adult patients with newly-diagnosed glioblastoma multiforme concomitantly with radiotherapy

(RT) and subsequently as monotherapy treatment.

* children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after

standard therapy.

**4.2 Posology and method of administration**

Temozolomide SUN should only be prescribed by physicians experienced in the oncological treatment of brain tumours.

Anti-emetic therapy may be administered (see section 4.4).

Posology

*Adult patients with newly-diagnosed glioblastoma multiforme*

Temozolomide SUN is administered in combination with focal radiotherapy (concomitant phase) followed by up to 6 cycles of temozolomide (TMZ) monotherapy (monotherapy phase).

*Concomitant phase*

TMZ is administered orally at a dose of 75 mg/m2 daily for 42 days concomitant with focal radiotherapy (60 Gy administered in 30 fractions). No dose reductions are recommended, but delay or discontinuation of TMZ administration should be decided weekly according to haematological and non-haematological toxicity criteria. TMZ administration can be continued throughout the 42 day concomitant period (up to 49 days) if all of the following conditions are met:

- absolute neutrophil count (ANC) ≥ 1.5 x 109/l

- thrombocyte count ≥ 100 x 109/l

- common toxicity criteria (CTC) non-haematological toxicity ≤ Grade 1 (except for alopecia, nausea and vomiting).

During treatment a complete blood count should be obtained weekly. TMZ administration should be temporarily interrupted or permanently discontinued during the concomitant phase according to the haematological and non-haematological toxicity criteria as noted in Table 1.

 *Table 1. TMZ dosing interruption or discontinuation during concomitant radiotherapy and TMZ*

|  |  |  |
| --- | --- | --- |
| Toxicity | TMZ interruptiona | TMZ discontinuation |
| Absolute neutrophil count | ≥ 0.5 and < 1.5 x 109/l |  < 0.5 x 109/l |
| Thrombocyte count | ≥ 10 and < 100 x 109/l | < 10 x 109/l |
| CTC non-haematological toxicity (except for alopecia, nausea, vomiting) | CTC Grade 2 | CTC Grade 3 or 4 |

a: Treatment with concomitant TMZ can be continued when all of the following conditions are met:

 absolute neutrophil count ≥ 1.5 x 109/l; thrombocyte count ≥ 100 x 109/l; CTC non-haematological

 toxicity ≤ Grade 1 (except for alopecia, nausea, vomiting).

*Monotherapy phase*

Four weeks after completing the TMZ + RT concomitant phase, TMZ is administered for up to 6 cycles of monotherapy treatment. Dose in Cycle 1 (monotherapy) is 150 mg/m2 once daily for 5 days followed by 23 days without treatment. At the start of Cycle 2, the dose is escalated to 200 mg/m2 if the CTC non-haematological toxicity for Cycle 1 is Grade ≤ 2 (except for alopecia, nausea and vomiting), absolute neutrophil count (ANC) is ≥ 1.5 x 109/l, and the thrombocyte count is ≥ 100 x 109/l. If the dose was not escalated at Cycle 2, escalation should not be done in subsequent cycles. Once escalated, the dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs. Dose reductions and discontinuations during the monotherapy phase should be applied according to Tables 2 and 3.

During treatment a complete blood count should be obtained on Day 22 (21 days after the first dose of TMZ). The dose should be reduced or administration discontinued according to Table 3.

 *Table 2. TMZ dose levels for monotherapy treatment*

|  |  |  |
| --- | --- | --- |
| Dose level | TMZ dose(mg/m2/day) | Remarks |
| -1 | 100 | Reduction for prior toxicity |
| 0 | 150 | Dose during Cycle 1 |
| 1 | 200 | Dose during Cycles 2-6 in absence of toxicity |

*Table 3. TMZ dose reduction or discontinuation during monotherapy treatment*

|  |  |  |
| --- | --- | --- |
| Toxicity | Reduce TMZ by 1 dose levela | Discontinue TMZ |
| Absolute neutrophil count | < 1.0 x 109/l | See footnote b |
| Thrombocyte count | < 50 x 109/l | See footnote b |
| CTC non-haematological Toxicity (except for alopecia, nausea, vomiting) | CTC Grade 3 | CTC Grade 4b |

a: TMZ dose levels are listed in Table 2.

b: TMZ is to be discontinued if:

* dose level -1 (100 mg/m2) still results in unacceptable toxicity
* the same Grade 3 non-haematological toxicity (except for alopecia, nausea, vomiting) recurs after dose reduction.

*Adult and paediatric patients 3 years of age or older with recurrent or progressive malignant glioma*

A treatment cycle comprises 28 days. In patients previously untreated with chemotherapy, TMZ is administered orally at a dose of 200 mg/m2 once daily for the first 5 days followed by a 23 day treatment interruption (total of 28 days). In patients previously treated with chemotherapy, the initial dose is 150 mg/m2 once daily, to be increased in the second cycle to 200 mg/m2 once daily, for 5 days if there is no haematological toxicity (see section 4.4)

*Special populations*

*Paediatric population*

In patients 3 years of age or older, TMZ is only to be used in recurrent or progressive malignant glioma. Experience in these children is very limited (see sections 4.4 and 5.1). The safety and efficacy of TMZ in children under the age of 3 years have not been established. No data are available.

*Patients with hepatic or renal impairment*

The pharmacokinetics of TMZ were comparable in patients with normal hepatic function and in those with mild or moderate hepatic impairment. No data are available on the administration of TMZ in patients with severe hepatic impairment (Child’s Class C) or with renal impairment. Based on the pharmacokinetic properties of TMZ, it is unlikely that dose reductions are required in patients with severe hepatic impairment or any degree of renal impairment. However, caution should be exercised when TMZ is administered in these patients.

*Elderly patients*

Based on a population pharmacokinetic analysis in patients 19-78 years of age, clearance of TMZ is not affected by age. However, elderly patients (> 70 years of age) appear to be at increased risk of neutropenia and thrombocytopenia (see section 4.4).

Method of administration

Temozolomide SUN should be administered in the fasting state.

The capsules must be swallowed whole with a glass of water and must not be opened or chewed.

If vomiting occurs after the dose is administered, a second dose should not be administered that day.

**4.3 Contraindications**

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Hypersensitivity to dacarbazine (DTIC).

Severe myelosuppression (see section 4.4).

**4.4 Special warnings and precautions for use**

*Opportunistic infections and reactivation of infections*

Opportunistic infections (such as Pneumocystis jirovecii pneumonia) and reactivation of infections (such as HBV, CMV) have been observed during the treatment with TMZ (see section 4.8).

*Meningoencephalitis herpetic*

In post-marketing cases, meningoencephalitis herpetic (including fatal cases) has been observed in patients receiving TMZ in combination with radiotherapy, including cases of concomitant steroids administration.

*Pneumocystis jirovecii* pneumonia

Patients who received concomitant TMZ and RT in a pilot trial for the prolonged 42-day schedule were shown to be at particular risk for developing *Pneumocystis jirovecii* pneumonia (PCP). Thus, prophylaxis against PCP is required for all patients receiving concomitant TMZ and RT for the 42-day regimen (with a maximum of 49 days) regardless of lymphocyte count. If lymphopenia occurs, they are to continue the prophylaxis until recovery of lymphopenia to grade ≤ 1.

There may be a higher occurrence of PCP when TMZ is administered during a longer dosing regimen. However, all patients receiving TMZ, particularly patients receiving steroids, should be observed closely for the development of PCP, regardless of the regimen. Cases of fatal respiratory failure have been reported in patients using TMZ, in particular in combination with dexamethasone or other steroids.

HBV

Hepatitis due to hepatitis B virus (HBV) reactivation, in some cases resulting in death, has been reported. Experts in liver disease should be consulted before treatment is initiated in patients with positive hepatitis B serology (including those with active disease). During treatment patients should be monitored and managed appropriately.

Hepatotoxicity

Hepatic injury, including fatal hepatic failure, has been reported in patients treated with TMZ (see section 4.8). Baseline liver function tests should be performed prior to treatment initiation. If abnormal, physicians should assess the benefit/risk prior to initiating temozolomide including the potential for fatal hepatic failure. For patients on a 42 day treatment cycle liver function tests should be repeated midway during this cycle. For all patients, liver function tests should be checked after each treatment cycle. For patients with significant liver function abnormalities, physicians should assess the benefit/risk of continuing treatment. Liver toxicity may occur several weeks or more after the last treatment with temozolomide.

Malignancies

Cases of myelodysplastic syndrome and secondary malignancies, including myeloid leukaemia, have also been reported very rarely (see section 4.8).

Anti-emetic therapy

Nausea and vomiting are very commonly associated with TMZ.

Anti-emetic therapy may be administered prior to or following administration of TMZ.

*Adult patients with newly-diagnosed glioblastoma multiforme*

Anti-emetic prophylaxis is recommended prior to the initial dose of concomitant phase and it is strongly recommended during the monotherapy phase.

*Patients with recurrent or progressive malignant glioma*

Patients who have experienced severe (Grade 3 or 4) vomiting in previous treatment cycles may require anti-emetic therapy.

Laboratory parameters

Patients treated with TMZ may experience myelosuppression, including prolonged pancytopenia, which may result in aplastic anaemia, which in some cases has resulted in a fatal outcome. In some cases, exposure to concomitant medicinal products associated with aplastic anaemia, including carbamazepine, phenytoin, and sulfamethoxazole/trimethoprim, complicates assessment. Prior to dosing, the following laboratory parameters must be met: ANC ≥ 1.5 x 109/l and platelet count ≥ 100 x 109/l. A complete blood count should be obtained on Day 22 (21 days after the first dose) or within 48 hours of that day, and weekly until ANC > 1.5 x 109/l and platelet count > 100 x 109/l. If ANC falls to < 1.0 x 109/l or the platelet count is < 50 x 109/l during any cycle, the next cycle should be reduced one dose level (see section 4.2). Dose levels include 100 mg/m2, 150 mg/m2, and 200 mg/m2. The lowest recommended dose is 100 mg/m2.

Paediatric population

There is no clinical experience with use of TMZ in children under the age of 3 years. Experience in older children and adolescents is very limited (see sections 4.2 and 5.1).

Elderly patients (> 70 years of age)

Elderly patients appear to be at increased risk of neutropenia and thrombocytopenia, compared with younger patients. Therefore, special care should be taken when TMZ is administered in elderly patients.

Female patients

Women of childbearing potential have to use effective contraception to avoid pregnancy while they are receiving TMZ, and for at least 6 months following completion of treatment.

Male patients

Men being treated with TMZ should be advised not to father a child for at least 3 months after receiving the last dose and to seek advice on cryoconservation of sperm prior to treatment (see section 4.6).

Lactose

This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.

**4.5 Interaction with other medicinal products and other forms of interaction**

In a separate phase I study, administration of TMZ with ranitidine did not result in alterations in the extent of absorption of temozolomide or the exposure to its active metabolite monomethyl triazenoimidazole carboxamide (MTIC).

Administration of TMZ with food resulted in a 33 % decrease in Cmax and a 9 % decrease in area under the curve (AUC).

As it cannot be excluded that the change in Cmax is clinically significant, Temozolomide SUN should be administered without food.

Based on an analysis of population pharmacokinetics in phase II trials, co-administration of dexamethasone, prochlorperazine, phenytoin, carbamazepine, ondansetron, H2 receptor antagonists, or phenobarbital did not alter the clearance of TMZ. Co-administration with valproic acid was associated with a small but statistically significant decrease in clearance of TMZ.

No studies have been conducted to determine the effect of TMZ on the metabolism or elimination of other medicinal products. However, since TMZ does not undergo hepatic metabolism and exhibits low protein binding, it is unlikely that it would affect the pharmacokinetics of other medicinal products (see section 5.2).

Use of TMZ in combination with other myelosuppressive agents may increase the likelihood of myelosuppression.

Paediatric population

Interaction studies have only been performed in adults.

**4.6 Fertility, pregnancy and lactation**

Women of childbearing potential

Women of childbearing potential have to use effective contraception to avoid pregnancy while they are receiving TMZ, and for at least 6 months following completion of treatment.

Pregnancy

There are no data in pregnant women. In preclinical studies in rats and rabbits receiving 150 mg/m2 TMZ, teratogenicity and/or foetal toxicity were demonstrated (see section 5.3). Temozolomide SUN should not be administered to pregnant women. If use during pregnancy must be considered, the patient should be apprised of the potential risk to the foetus.

Breast-feeding

It is not known whether TMZ is excreted in human milk; thus, breast-feeding should be discontinued while receiving treatment with TMZ.

Male fertility

TMZ can have genotoxic effects. Therefore, men being treated with it should use effective contraceptive measures and be advised not to father a child for at least 3 months after receiving the last dose and to seek advice on cryoconservation of sperm prior to treatment, because of the possibility of irreversible infertility due to therapy with TMZ.

**4.7 Effects on ability to drive and use machines**

TMZ has minor influence on the ability to drive and use machines due to fatigue and somnolence (see section 4.8).

**4.8 Undesirable effects**

Summary of the safety profile

Clinical trial experience

In patients treated with TMZ in clinical trials, the most common adverse reactions were nausea, vomiting, constipation, anorexia, headache, fatigue, convulsions, and rash. Most haematologic adverse reactions were reported commonly; the frequency of Grade 3-4 laboratory findings is presented after Table 4.

For patients with recurrent or progressive glioma, nausea (43 %) and vomiting (36 %) were usually Grade 1 or 2 (0 – 5 episodes of vomiting in 24 hours) and were either self-limiting or readily controlled with standard anti-emetic therapy. The incidence of severe nausea and vomiting was 4 %.

Tabulated list of adverse reactions

Adverse reactions observed in clinical studies and reported from post-marketing use of TMZ are listed in Table 4. These reactions are classified according to System Organ Class and frequency. Frequency groupings are defined according to the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); Rare (≥1/10,000 to <1/1,000); Very rare (<1/10,000); Not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

| *Table 4. Adverse reactions in patients treated with temozolomide* |
| --- |
| **Infections and infestations** |
| Common: | Infections, herpes zoster, pharyngitisa, candidiasis oral |
| Uncommon: | Opportunistic infection (including PCP), sepsis†, meningoencephalitis herpetic†, CMV infection, CMV reactivation, hepatitis B virus†, herpes simplex, infection reactivation, wound infection, gastroenteritisb |
| **Neoplasm benign, malignant, and unspecified** |
| Uncommon: | Myelodysplastic syndrome (MDS), secondary malignancies, including myeloid leukaemia |
| **Blood and lymphatic system disorders** |
| Common: | Febrile neutropenia, neutropenia, thrombocytopenia, lymphopenia, leukopenia, anaemia |
| Uncommon: | Prolonged pancytopenia, aplastic anaemia†, pancytopenia, petechiae |
| **Immune system disorders** |
| Common: | Allergic reaction |
| Uncommon: | Anaphylaxis |
| **Endocrine disorders** |
| Common: | Cushingoidc |
| Uncommon: | Diabetes insipidus |
| **Metabolism and nutrition disorders** |
| Very common: | Anorexia |
| Common: | Hyperglycaemia |
| Uncommon: | Hypokalaemia, alkaline phosphatase increased |
| **Psychiatric disorders** |
| Common: | Agitation, amnesia, depression, anxiety, confusion, insomnia |
| Uncommon: | Behaviour disorder, emotional lability, hallucination, apathy |
| **Nervous system disorders** |
| Very common: | Convulsions, hemiparesis, aphasia/dysphasia, headache |
| Common: | Ataxia, balance impaired, cognition impaired, concentration impaired, consciousness decreased, dizziness, hypoesthesia, memory impaired, neurologic disorder, neuropathyd, paraesthesia, somnolence, speech disorder, taste perversion, tremor |
| Uncommon: | Status epilepticus, hemiplegia, extrapyramidal disorder, parosmia, gait abnormality, hyperaesthesia, sensory disturbance, coordination abnormal |
| **Eye disorders** |
| Common: | Hemianopia, vision blurred, vision disordere, visual field defect, diplopia, eye pain |
| Uncommon: | Visual acuity reduced, eyes dry |
| **Ear and labyrinth disorders** |
| Common: | Deafnessf, vertigo, tinnitus, earacheg |
| Uncommon: | Hearing impairment, hyperacusis, otitis media |
| **Cardiac disorders** |
| Uncommon: | Palpitation |
| **Vascular disorders** |
| Common: | Haemorrhage, embolism pulmonary, deep vein thrombosis, hypertension  |
| Uncommon: | Cerebral haemorrhage, flushing, hot flushes |
| **Respiratory, thoracic and mediastinal disorders** |
| Common: | Pneumonia, dyspnoea, sinusitis, bronchitis, coughing, upper respiratory infection |
| Uncommon: | Respiratory failure†, interstitial pneumonitis/pneumonitis, pulmonary fibrosis, nasal congestion |
| **Gastrointestinal disorders** |
| Very common: | Diarrhoea, constipation, nausea, vomiting |
| Common: | Stomatitis, abdominal painh, dyspepsia, dysphagia  |
| Uncommon: | Abdominal distension, faecal incontinence, gastrointestinal disorder, haemorrhoids, mouth dry |
| **Hepatobiliary disorders** |
| Uncommon: | Hepatic failure†, hepatic injury, hepatitis, cholestasis, hyperbilirubinemia |
| **Skin and subcutaneous tissue disorders** |
| Very Common: | Rash, alopecia |
| Common: | Erythema, dry skin, pruritus |
| Uncommon: | Toxic epidermal necrolysis, Stevens-Johnson syndrome, angioedema, erythema multiforme, erythroderma, skin exfoliation, photosensitivity reaction, urticaria, exanthema, dermatitis, sweating increased, pigmentation abnormal |
| Not known: | Drug reaction with eosinophilia and systemic symptoms (DRESS) |
| **Musculoskeletal and connective tissue disorders** |
| Common: | Myopathy, muscle weakness, arthralgia, back pain, musculoskeletal pain, myalgia  |
| **Renal and urinary disorders** |
| Common: | Micturition frequency, urinary incontinence  |
| Uncommon: | Dysuria |
| **Reproductive system and breast disorders** |
| Uncommon: | Vaginal haemorrhage, menorrhagia, amenorrhoea, vaginitis, breast pain, impotence |
| **General disorders and administration site conditions** |
| Very common: | Fatigue |
| Common: | Fever, influenza-like symptoms, asthenia, malaise, pain, oedema, oedema peripherali |
| Uncommon: | Condition aggravated, rigors, face oedema, tongue discolouration, thirst, tooth disorder |
| **Investigations** |
| Common: | Liver enzymes elevationj, weight decreased, weight increased |
| Uncommon: | Gamma-glutamyltransferase increased |
| **Injury, poisoning and procedural complications**  |
| Common: | Radiation injuryk |
| a Includes pharyngitis, nasopharyngeal pharyngitis, pharyngitis Streptococcal b Includes gastroenteritis, gastroenteritis viralc Includes cushingoid, Cushing syndromed Includes neuropathy, peripheral neuropathy, polyneuropathy, peripheral sensory neuropathy, peripheral motor neuropathye Includes visual impairment, eye disorderf Includes deafness, deafness bilateral, deafness neurosensory, deafness unilateralg Includes earache, ear discomforth Includes abdominal pain, abdominal pain lower, abdominal pain upper, abdominal discomforti Includes oedema peripheral, peripheral swellingj Includes liver function test increased, alanine aminotransferase increased, aspartate aminotransferase increased, hepatic enzymes increasedk Includes radiation injury, radiation skin injury† Including cases with fatal outcome |

*Newly-diagnosed glioblastoma multiforme*

*Laboratory results*

Myelosuppression (neutropenia and thrombocytopenia), which is known dose-limiting toxicity for most cytotoxic agents, including TMZ, was observed. When laboratory abnormalities and adverse events were combined across concomitant and monotherapy treatment phases, Grade 3 or Grade 4 neutrophil abnormalities including neutropenic events were observed in 8 % of the patients. Grade 3 or Grade 4 thrombocyte abnormalities, including thrombocytopenic events were observed in 14 % of the patients who received TMZ.

*Recurrent or progressive malignant glioma*

*Laboratory results*

Grade 3 or 4 thrombocytopenia and neutropenia occurred in 19 % and 17 % respectively, of patients treated for malignant glioma. This led to hospitalisation and/or discontinuation of TMZ in 8 % and 4 %, respectively. Myelosuppression was predictable (usually within the first few cycles, with the nadir between Day 21 and Day 28), and recovery was rapid, usually within 1-2 weeks. No evidence of cumulative myelosuppression was observed. The presence of thrombocytopenia may increase the risk of bleeding, and the presence of neutropenia or leukopenia may increase the risk of infection.

*Gender*

In a population pharmacokinetics analysis of clinical trial experience there were 101 female and 169 male subjects for whom nadir neutrophil counts were available and 110 female and 174 male subjects for whom nadir platelet counts were available. There were higher rates of Grade 4 neutropenia (ANC < 0.5 x 109/l), 12 % *vs* 5 %, and thrombocytopenia (< 20 x 109/l ), 9 % *vs* 3 %, in women *vs* men in the first cycle of therapy. In a 400 subject recurrent glioma data set, Grade 4 neutropenia occurred in 8 % of female *vs* 4 % of male subjects and Grade 4 thrombocytopenia in 8 % of female *vs* 3 % of male subjects in the first cycle of therapy. In a study of 288 subjects with newly-diagnosed glioblastoma multiforme, Grade 4 neutropenia occurred in 3 % of female *vs* 0 % of male subjects and Grade 4 thrombocytopenia in 1 % of female *vs* 0 % of male subjects in the first cycle of therapy.

Paediatric population

Oral TMZ has been studied in paediatric patients (age 3-18 years) with recurrent brainstem glioma or recurrent high grade astrocytoma, in a regimen administered daily for 5 days every 28 days. Although the data is limited, tolerance in children is expected to be the same as in adults. The safety of TMZ in children under the age of 3 years has not been established.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in [Appendix V](http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc).

**4.9 Overdose**

Doses of 500, 750, 1,000, and 1,250 mg/m2 (total dose per cycle over 5 days) have been evaluated clinically in patients. Dose-limiting toxicity was haematological and was reported with any dose but is expected to be more severe at higher doses. An overdose of 10,000 mg (total dose in a single cycle, over 5 days) was taken by one patient and the adverse reactions reported were pancytopenia, pyrexia, multiorgan failure and death. There are reports of patients who have taken the recommended dose for more than 5 days of treatment (up to 64 days) with adverse events reported including bone marrow suppression, with or without infection, in some cases severe and prolonged and resulting in death. In the event of an overdose, haematological evaluation is needed. Supportive measures should be provided as necessary.

**5. PHARMACOLOGICAL PROPERTIES**

**5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Antineoplastic agents, other alkylating agents, ATC code: L01A X03.

Mechanism of action

Temozolomide is a triazene, which undergoes rapid chemical conversion at physiologic pH to the active monomethyl triazenoimidazole carboxamide (MTIC). The cytotoxicity of MTIC is thought to be due primarily to alkylation at the O6 position of guanine with additional alkylation also occurring at the N7 position. Cytotoxic lesions that develop subsequently are thought to involve aberrant repair of the methyl adduct.

Clinical efficacy and safety

*Newly-diagnosed glioblastoma multiforme*

A total of 573 patients were randomised to receive either TMZ + RT (n=287) or RT alone (n=286). Patients in the TMZ + RT arm received concomitant TMZ (75 mg/m2) once daily, starting the first day of RT until the last day of RT, for 42 days (with a maximum of 49 days). This was followed by monotherapy TMZ (150-200 mg/m2) on Days 1-5 of every 28-day cycle for up to 6 cycles, starting 4 weeks after the end of RT. Patients in the control arm received RT only. *Pneumocystis jirovecii*pneumonia (PCP) prophylaxis was required during RT and combined TMZ therapy.

TMZ was administered as salvage therapy in the follow-up phase in 161 patients of the 282 (57 %) in the RT alone arm, and 62 patients of the 277 (22 %) in the TMZ + RT arm.

The hazard ratio (HR) for overall survival was 1.59 (95 % CI for HR=1.33-1.91) with a log-rank p < 0.0001 in favour of the TMZ arm. The estimated probability of surviving 2 years or more (26 % *vs* 10 %) is higher for the RT + TMZ arm. The addition of concomitant TMZ to RT, followed by TMZ monotherapy in the treatment of patients with newly-diagnosed glioblastoma multiforme demonstrated a statistically significant improvement in overall survival (OS) compared with RT alone (Figure 1).

 *Figure 1 Kaplan-Meier curves for overall survival (intent-to-treat population)*



The results from the trial were not consistent in the subgroup of patients with a poor performance status (WHO PS=2, n=70), where overall survival and time to progression were similar in both arms.

However, no unacceptable risks appear to be present in this patient group.

*Recurrent or progressive malignant glioma*

Data on clinical efficacy in patients with glioblastoma multiforme (Karnofsky performance status [KPS] ≥ 70), progressive or recurrent after surgery and RT, were based on two clinical trials with oral TMZ. One was a non-comparative trial in 138 patients (29 % received prior chemotherapy), and the other was a randomised active-controlled trial of TMZ *vs* procarbazine in a total of 225 patients (67 % received prior treatment with nitrosourea based chemotherapy). In both trials, the primary endpoint was progression-free survival (PFS) defined by MRI scans or neurological worsening. In the noncomparative trial, the PFS at 6 months was 19 %, the median progression-free survival was 2.1 months, and the median overall survival 5.4 months. The objective response rate (ORR) based on MRI scans was 8 %.

In the randomised active-controlled trial, the PFS at 6 months was significantly greater for TMZ than for procarbazine (21 % *vs* 8 %, respectively – chi-square p=0.008) with median PFS of 2.89 and 1.88 months respectively (log rank p=0.0063). The median survival was 7.34 and 5.66 months for TMZ and procarbazine, respectively (log rank p=0.33). At 6 months, the fraction of surviving patients was significantly higher in the TMZ arm (60 %) compared with the procarbazine arm (44 %) (chi-square p=0.019). In patients with prior chemotherapy a benefit was indicated in those with a KPS ≥ 80.

Data on time to worsening of neurological status favoured TMZ over procarbazine as did data on time to worsening of performance status (decrease to a KPS of < 70 or a decrease by at least 30 points). The median times to progression in these endpoints ranged from 0.7 to 2.1 months longer for TMZ than for procarbazine (log rank p=< 0.01 to 0.03).

*Recurrent anaplastic astrocytoma*

In a multicentre, prospective phase II trial evaluating the safety and efficacy of oral TMZ in the treatment of patients with anaplastic astrocytoma at first relapse, the 6 month PFS was 46 %. The median PFS was 5.4 months. Median overall survival was 14.6 months. Response rate, based on the central reviewer assessment, was 35 % (13 CR and 43 PR) for the intent-to-treat population (ITT) n=162. In 43 patients stable disease was reported. The 6-month event-free survival for the ITT population was 44 % with a median event-free survival of 4.6 months, which was similar to the results for the progression-free survival. For the eligible histology population, the efficacy results were similar. Achieving a radiological objective response or maintaining progression-free status was strongly associated with maintained or improved quality of life.

Paediatric population

Oral TMZ has been studied in paediatric patients (age 3-18 years) with recurrent brainstem glioma or recurrent high grade astrocytoma, in a regimen administered daily for 5 days every 28 days. Tolerance to TMZ is similar to adults.

**5.2 Pharmacokinetic properties**

TMZ is spontaneously hydrolyzed at physiologic pH primarily to the active species, 3-methyl-(triazen-1-yl)imidazole-4-carboxamide (MTIC). MTIC is spontaneously hydrolyzed to 5-amino-imidazole-4-carboxamide (AIC), a known intermediate in purine and nucleic acid biosynthesis, and to methylhydrazine, which is believed to be the active alkylating species. The cytotoxicity of MTIC is thought to be primarily due to alkylation of DNA mainly at the O6 and N7 positions of guanine. Relative to the AUC of TMZ, the exposure to MTIC and AIC is ~ 2.4 % and 23 %, respectively. *In vivo*, the t1/2 of MTIC was similar to that of TMZ, 1.8 hr.

Absorption

After oral administration to adult patients, TMZ is absorbed rapidly, with peak concentrations reached as early as 20 minutes post-administration (mean time between 0.5 and 1.5 hours). After oral administration of 14C-labelled TMZ, mean faecal excretion of 14C over 7 days post-dose was 0.8 % indicating complete absorption.

Distribution

TMZ demonstrates low protein binding (10 % to 20 %), and thus it is not expected to interact with highly protein-bound substances.

PET studies in humans and preclinical data suggest that TMZ crosses the blood-brain barrier rapidly and is present in the CSF. CSF penetration was confirmed in one patient; CSF exposure based on AUC of TMZ was approximately 30 % of that in plasma, which is consistent with animal data.

Elimination

The half-life (t1/2) in plasma is approximately 1.8 hours. The major route of 14C elimination is renal. Following oral administration, approximately 5 % to 10 % of the dose is recovered unchanged in the urine over 24 hours, and the remainder excreted as temozolomide acid, 5-aminoimidazole-4-carboxamide (AIC) or unidentified polar metabolites.

Plasma concentrations increase in a dose-related manner. Plasma clearance, volume of distribution and half-life are independent of dose.

Special populations

Analysis of population-based pharmacokinetics of TMZ revealed that plasma TMZ clearance was independent of age, renal function or tobacco use. In a separate pharmacokinetic study, plasma pharmacokinetic profiles in patients with mild to moderate hepatic impairment were similar to those observed in patients with normal hepatic function.

Paediatric patients had a higher AUC than adult patients; however, the maximum tolerated dose (MTD) was 1,000 mg/m2 per cycle both in children and in adults.

**5.3 Preclinical safety data**

Single-cycle (5-day dosing, 23 days non-treatment), 3- and 6-cycle toxicity studies were conducted in rats and dogs. The primary targets of toxicity included the bone marrow, lymphoreticular system, testes, the gastrointestinal tract and, at higher doses, which were lethal to 60 % to 100 % of rats and dogs tested, degeneration of the retina occurred. Most of the toxicity showed evidence of reversibility, except for adverse events on the male reproductive system and retinal degeneration. However, because the doses implicated in retinal degeneration were in the lethal dose range, and no comparable effect has been observed in clinical studies, this finding was not considered to have clinical relevance.

TMZ is an embryotoxic, teratogenic and genotoxic alkylating agent. TMZ is more toxic to the rat and dog than to humans, and the clinical dose approximates the minimum lethal dose in rats and dogs. Dose-related reductions in leukocytes and platelets appear to be sensitive indicators of toxicity. A variety of neoplasms, including mammary carcinomas, keratocanthoma of the skin and basal cell adenoma were observed in the 6-cycle rat study while no tumours or pre-neoplastic changes were evident in dog studies. Rats appear to be particularly sensitive to oncogenic effects of TMZ, with the occurrence of first tumours within 3 months of initiating dosing. This latency period is very short even for an alkylating agent.

Results of the Ames/salmonella and Human Peripheral Blood Lymphocyte (HPBL) chromosome aberration tests showed a positive mutagenicity response.

**6. PHARMACEUTICAL PARTICULARS**

**6.1 List of excipients**

5 mg hard capsules

Capsule content

Lactose

Sodium starch glycolate (Type B)

Tartaric acid

Stearic acid

Capsule shell

Gelatin

Titanium dioxide (E171)

Sodium laurilsulfate

Printing ink

Shellac

Propylene glycol

Yellow iron oxide (E172)

Blue #1/Brilliant Blue FCF Aluminium Lake (E133)

20 mg hard capsules

Capsule content

Lactose

Sodium starch glycolate (Type B)

Tartaric acid

Stearic acid

Capsule shell

Gelatin

Titanium dioxide (E171)

Sodium laurilsulfate

Printing ink

Shellac

Propylene glycol

Yellow iron oxide (E172)

100 mg hard capsules

Capsule content

Lactose

Sodium starch glycolate (Type B)

Tartaric acid

Stearic acid

Capsule shell

Gelatin

Titanium dioxide (E171)

Sodium laurilsulfate

Printing ink

Shellac

Propylene glycol

Red iron oxide (E172)

Yellow iron oxide (E172)

Titanium dioxide (E171)

140 mg hard capsules

Capsule content

Lactose

Sodium starch glycolate (Type B)

Tartaric acid

Stearic acid

Capsule shell

Gelatin

Titanium dioxide (E171)

Sodium laurilsulfate

Printing ink

Shellac

Propylene glycol

Titanium dioxide (E171)

Blue #1/Brilliant Blue FCF Aluminium Lake (E133)

180 mg hard capsules

Capsule content

Lactose

Sodium starch glycolate (Type B)

Tartaric acid

Stearic acid

Capsule shell

Gelatin

Titanium dioxide (E171)

Sodium laurilsulfate

Printing ink

Shellac

Propylene glycol

Red iron oxide (E172)

250 mg hard capsules

Capsule content

Lactose

Sodium starch glycolate (Type B)

Tartaric acid

Stearic acid

Capsule shell

Gelatin

Titanium dioxide (E171)

Sodium laurilsulfate

Printing ink

Shellac

Propylene glycol

Black iron oxide (E172)

**6.2 Incompatibilities**

Not applicable.

**6.3 Shelf life**

2 years

**6.4 Special precautions for storage**

Do not store above 25°C.

**6.5 Nature and contents of container**

Aluminium/aluminium unit dose blisters, consisting of an OPA [Oriented Poly Amide] / Aluminium / PVC [Polyvinyl chloride] forming film and peelable Aluminium lidding foil with heat seal laquer.

Pack size: blisters are packed in cartons containing 5 or 20 hard capsules.

Not all pack sizes may be marketed.

**6.6 Special precautions for disposal and other handling**

Capsules should not be opened. If a capsule becomes damaged, contact of the powder contents with skin or mucous membrane must be avoided. If Temozolomide SUN comes into contact with skin or mucosa, it should be washed immediately and thoroughly with soap and water.

Patients should be advised to keep capsules out of the sight and reach of children, preferably in a locked cupboard. Accidental ingestion can be lethal for children.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

**7. MARKETING AUTHORISATION HOLDER**

Sun Pharmaceutical Industries Europe B.V.

Polarisavenue 87

2132 JH Hoofddorp

The Netherlands

**8. MARKETING AUTHORISATION NUMBER(S)**

5 mg hard capsules

EU/1/11/697/013 (5 capsules in blister)

EU/1/11/697/014 (20 capsules in blister)

20 mg hard capsules

EU/1/11/697/015 (5 capsules in blister)

EU/1/11/697/016 (20 capsules in blister)

100 mg hard capsules

EU/1/11/697/017 (5 capsules in blister)

EU/1/11/697/018 (20 capsules in blister)

140 mg hard capsules

EU/1/11/697/019 (5 capsules in blister)

EU/1/11/697/020 (20 capsules in blister)

180 mg hard capsules

EU/1/11/697/021 (5 capsules in blister)

EU/1/11/697/022 (20 capsules in blister)

250 mg hard capsules

EU/1/11/697/023 (5 capsules in blister)

EU/1/11/697/024 (20 capsules in blister)

**9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorization: 13 July 2011

Date of latest renewal: 21 April 2016

**10. DATE OF REVISION OF THE TEXT**

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu

**ANNEX II**

A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

##### **B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**

##### **C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**

**D. conditions or restrictions with regard to the safe and effective use of the medicinal product**

**A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE**

Name and address of the manufacturer responsible for batch release

Sun Pharmaceutical Industries Europe BV

Polarisavenue 87

2132 JH Hoofddorp

The Netherlands

The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.

**B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**

Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2).

**C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**

**• Periodic safety update reports (PSURs)**

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

1. **CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT**

• **Risk Management Plan (RMP)**

Not applicable.

**ANNEX III**

**LABELLING AND PACKAGE LEAFLET**

**A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**CARTON (BLISTER)**

**1. NAME OF THE MEDICINAL PRODUCT**

Temozolomide SUN 5 mg hard capsules

temozolomide

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each hard capsule contains 5 mg temozolomide.

**3. LIST OF EXCIPIENTS**

Contains lactose. See package leaflet for further information.

**4. PHARMACEUTICAL FORM AND CONTENTS**

5x1 hard capsule

20x1 hard capsule

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.

Oral use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children, preferably in a locked cupboard. Accidental ingestion can be lethal for children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

Cytotoxic.

Do not open, crush or chew the capsules, swallow whole. If a capsule is damaged, avoid contact with your skin, eyes or nose.

**8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

Do not store above 25°C.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Sun Pharmaceutical Industries Europe B.V.

Polarisavenue 87

2132 JH Hoofddorp

The Netherlands

**12. MARKETING AUTHORISATION NUMBER(S)**

EU/1/11/697/013 (5 hard capsules)

EU/1/11/697/014 (20 hard capsules)

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

Medicinal product subject to medical prescription.

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

Temozolomide SUN 5 mg

**17. UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

**18. UNIQUE IDENTIFIER – HUMAN READABLE DATA**

PC

SN

NN

|  |
| --- |
| **MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS****BLISTER** |

|  |
| --- |
| **1. NAME OF THE MEDICINAL PRODUCT**  |

Temozolomide SUN 5 mg hard capsules

temozolomide

Oral use

|  |
| --- |
| **2. NAME OF THE MARKETING AUTHORISATION HOLDER** |

SUN Pharma logo

|  |
| --- |
| **3. EXPIRY DATE** |

EXP

|  |
| --- |
| **4. BATCH NUMBER** |

Lot

|  |
| --- |
| **5. OTHER** |

PEEL

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**CARTON (BLISTER)**

**1. NAME OF THE MEDICINAL PRODUCT**

Temozolomide SUN 20 mg hard capsules

temozolomide

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each hard capsule contains 20 mg temozolomide.

**3. LIST OF EXCIPIENTS**

Contains lactose. See package leaflet for further information.

**4. PHARMACEUTICAL FORM AND CONTENTS**

5x1 hard capsule

20x1 hard capsule

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.

Oral use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children, preferably in a locked cupboard. Accidental ingestion can be lethal for children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

Cytotoxic.

Do not open, crush or chew the capsules, swallow whole. If a capsule is damaged, avoid contact with your skin, eyes or nose.

**8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

Do not store above 25°C.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Sun Pharmaceutical Industries Europe B.V.

Polarisavenue 87

2132 JH Hoofddorp

The Netherlands

**12. MARKETING AUTHORISATION NUMBER(S)**

EU/1/11/697/015 (5 hard capsules)

EU/1/11/697/016 (20 hard capsules)

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

Medicinal product subject to medical prescription.

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

Temozolomide SUN 20 mg

**17. UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

**18. UNIQUE IDENTIFIER – HUMAN READABLE DATA**

PC

SN

NN

|  |
| --- |
| **MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS****BLISTER** |

|  |
| --- |
| **1. NAME OF THE MEDICINAL PRODUCT**  |

Temozolomide SUN 20 mg hard capsules

temozolomide

Oral use

|  |
| --- |
| **2. NAME OF THE MARKETING AUTHORISATION HOLDER** |

SUN Pharma logo

|  |
| --- |
| **3. EXPIRY DATE** |

EXP

|  |
| --- |
| **4. BATCH NUMBER** |

Lot

|  |
| --- |
| **5. OTHER** |

PEEL

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**CARTON (BLISTER)**

**1. NAME OF THE MEDICINAL PRODUCT**

Temozolomide SUN 100 mg hard capsules

temozolomide

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each hard capsule contains 100 mg temozolomide.

**3. LIST OF EXCIPIENTS**

Contains lactose. See package leaflet for further information.

**4. PHARMACEUTICAL FORM AND CONTENTS**

5x1 hard capsule

20x1 hard capsule

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.

Oral use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children, preferably in a locked cupboard. Accidental ingestion can be lethal for children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

Cytotoxic.

Do not open, crush or chew the capsules, swallow whole. If a capsule is damaged, avoid contact with your skin, eyes or nose.

**8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

Do not store above 25°C.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Sun Pharmaceutical Industries Europe B.V.

Polarisavenue 87

2132 JH Hoofddorp

The Netherlands

**12. MARKETING AUTHORISATION NUMBER(S)**

EU/1/11/697/017 (5 hard capsules)

EU/1/11/697/018 (20 hard capsules)

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

Medicinal product subject to medical prescription.

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

Temozolomide SUN 100 mg

**17. UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

**18. UNIQUE IDENTIFIER – HUMAN READABLE DATA**

PC

SN

NN

|  |
| --- |
| **MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS****BLISTER** |

|  |
| --- |
| **1. NAME OF THE MEDICINAL PRODUCT**  |

Temozolomide SUN 100 mg hard capsules

temozolomide

Oral use

|  |
| --- |
| **2. NAME OF THE MARKETING AUTHORISATION HOLDER** |

SUN Pharma logo

|  |
| --- |
| **3. EXPIRY DATE** |

EXP

|  |
| --- |
| **4. BATCH NUMBER** |

Lot

|  |
| --- |
| **5. OTHER** |

PEEL

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**CARTON (BLISTER)**

**1. NAME OF THE MEDICINAL PRODUCT**

Temozolomide SUN 140 mg hard capsules

temozolomide

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each hard capsule contains 140 mg temozolomide.

**3. LIST OF EXCIPIENTS**

Contains lactose. See package leaflet for further information.

**4. PHARMACEUTICAL FORM AND CONTENTS**

5x1 hard capsule

20x1 hard capsule

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.

Oral use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children, preferably in a locked cupboard. Accidental ingestion can be lethal for children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

Cytotoxic.

Do not open, crush or chew the capsules, swallow whole. If a capsule is damaged, avoid contact with your skin, eyes or nose.

**8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

Do not store above 25°C.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Sun Pharmaceutical Industries Europe B.V.

Polarisavenue 87

2132 JH Hoofddorp

The Netherlands

**12. MARKETING AUTHORISATION NUMBER(S)**

EU/1/11/697/019 (5 hard capsules)

EU/1/11/697/020 (20 hard capsules)

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

Medicinal product subject to medical prescription.

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

Temozolomide SUN 140 mg

**17. UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

**18. UNIQUE IDENTIFIER – HUMAN READABLE DATA**

PC

SN

NN

|  |
| --- |
| **MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS****BLISTER** |

|  |
| --- |
| **1. NAME OF THE MEDICINAL PRODUCT**  |

Temozolomide SUN 140 mg hard capsules

temozolomide

Oral use

|  |
| --- |
| **2. NAME OF THE MARKETING AUTHORISATION HOLDER** |

SUN Pharma logo

|  |
| --- |
| **3. EXPIRY DATE** |

EXP

|  |
| --- |
| **4. BATCH NUMBER** |

Lot

|  |
| --- |
| **5. OTHER** |

PEEL

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**CARTON (BLISTER)**

**1. NAME OF THE MEDICINAL PRODUCT**

Temozolomide SUN 180 mg hard capsules

temozolomide

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each hard capsule contains 180 mg temozolomide.

**3. LIST OF EXCIPIENTS**

Contains lactose. See package leaflet for further information.

**4. PHARMACEUTICAL FORM AND CONTENTS**

5x1 hard capsule

20x1 hard capsule

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.

Oral use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children, preferably in a locked cupboard. Accidental ingestion can be lethal for children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

Cytotoxic.

Do not open, crush or chew the capsules, swallow whole. If a capsule is damaged, avoid contact with your skin, eyes or nose.

**8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

Do not store above 25°C.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Sun Pharmaceutical Industries Europe B.V.

Polarisavenue 87

2132 JH Hoofddorp

The Netherlands

**12. MARKETING AUTHORISATION NUMBER(S)**

EU/1/11/697/021 (5 hard capsules)

EU/1/11/697/022 (20 hard capsules)

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

Medicinal product subject to medical prescription.

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

Temozolomide SUN 180 mg

**17. UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

**18. UNIQUE IDENTIFIER – HUMAN READABLE DATA**

PC

SN

NN

|  |
| --- |
| **MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS****BLISTER** |

|  |
| --- |
| **1. NAME OF THE MEDICINAL PRODUCT**  |

Temozolomide SUN 180 mg hard capsules

temozolomide

Oral use

|  |
| --- |
| **2. NAME OF THE MARKETING AUTHORISATION HOLDER** |

SUN Pharma logo

|  |
| --- |
| **3. EXPIRY DATE** |

EXP

|  |
| --- |
| **4. BATCH NUMBER** |

Lot

|  |
| --- |
| **5. OTHER** |

PEEL

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**CARTON (BLISTER)**

**1. NAME OF THE MEDICINAL PRODUCT**

Temozolomide SUN 250 mg hard capsules

temozolomide

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each hard capsule contains 250 mg temozolomide.

**3. LIST OF EXCIPIENTS**

Contains lactose. See package leaflet for further information.

**4. PHARMACEUTICAL FORM AND CONTENTS**

5x1 hard capsule

20x1 hard capsule

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.

Oral use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children, preferably in a locked cupboard. Accidental ingestion can be lethal for children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

Cytotoxic.

Do not open, crush or chew the capsules, swallow whole. If a capsule is damaged, avoid contact with your skin, eyes or nose.

**8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

Do not store above 25°C.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Sun Pharmaceutical Industries Europe B.V.

Polarisavenue 87

2132 JH Hoofddorp

The Netherlands

**12. MARKETING AUTHORISATION NUMBER(S)**

EU/1/11/697/023 (5 hard capsules)

EU/1/11/697/024 (20 hard capsules)

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

Medicinal product subject to medical prescription.

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

Temozolomide SUN 250 mg

**17. UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

**18. UNIQUE IDENTIFIER – HUMAN READABLE DATA**

PC

SN

NN

|  |
| --- |
| **MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS****BLISTER** |

|  |
| --- |
| **1. NAME OF THE MEDICINAL PRODUCT**  |

Temozolomide SUN 250 mg hard capsules

temozolomide

Oral use

|  |
| --- |
| **2. NAME OF THE MARKETING AUTHORISATION HOLDER** |

SUN Pharma logo

|  |
| --- |
| **3. EXPIRY DATE** |

EXP

|  |
| --- |
| **4. BATCH NUMBER** |

Lot

|  |
| --- |
| **5. OTHER** |

PEEL

**B. PACKAGE LEAFLET**

**Package Leaflet: Information for the user**

**Temozolomide SUN 5 mg hard capsules**

**Temozolomide SUN 20 mg hard capsules**

**Temozolomide SUN 100 mg hard capsules**

**Temozolomide SUN 140 mg hard capsules**

**Temozolomide SUN 180 mg hard capsules**

**Temozolomide SUN 250 mg hard capsules**

temozolomide

**Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.**

1. Keep this leaflet. You may need to read it again.
2. If you have any further questions, ask your doctor, pharmacist or nurse.
3. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
4. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

**What is in this leaflet**

1. What Temozolomide SUN is and what it is used for

2. What you need to know before you take Temozolomide SUN

3. How to take Temozolomide SUN

4. Possible side effects

5. How to store Temozolomide SUN

6. Contents of the pack and other information

1. **What Temozolomide SUN is and what it is used for**

Temozolomide SUN contains a medicine called temozolomide. This medicine is an antitumour agent.

Temozolomide SUN is used for the treatment of specific forms of brain tumours:

1. in adults with newly-diagnosed glioblastoma multiforme. Temozolomide SUN is at first used together with radiotherapy (concomitant phase of treatment) and after that alone (monotherapy phase of treatment).
2. in children 3 years and older and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma. Temozolomide SUN is used in these tumours if they return or get worse after standard treatment.
3. **What you need to know before you take Temozolomide SUN**

**Do not take Temozolomide SUN**

- if you are allergic to temozolomide or any of the other ingredients of this medicine (listed in section 6).

- if you have had an allergic reaction to dacarbazine (an anticancer medicine sometimes called DTIC). Signs of allergic reaction include itchiness, breathlessness or wheezing, or swelling of the face, lips, tongue or throat.

* if the numbers of certain kinds of blood cells, such as your white blood cells or platelets are severely reduced (known as myelosuppression). These blood cells are important for fighting infection and for proper blood clotting. Your doctor will check your blood to make sure you have enough of these cells before you begin treatment.

**Warnings and precautions**

Talk to your doctor, pharmacist or nurse before taking Temozolomide SUN,

* as you should be observed closely for the development of a serious form of chest infection called *Pneumocystis jirovecii* pneumonia (PCP)*.* If you have been newly-diagnosed with glioblastoma multiforme you may be receiving Temozolomide SUN for 42 days in combination with radiotherapy. In this case, your doctor will also prescribe medicine to help you prevent this type of pneumonia (PCP).
* if you have ever had or might now have a hepatitis B infection. This is because Temozolomide SUN could cause hepatitis B to become active again, which can be fatal in some cases. Patients will be carefully checked by their doctor for signs of this infection before treatment is started.
* if you have low counts of red blood cells (anaemia), white blood cells and platelets, or blood clotting problems before starting the treatment, or if you develop them during treatment. Your blood will be tested frequently during treatment to monitor the side effects of Temozolomide SUN on your blood cells. Your doctor may decide to reduce the dose, interrupt, stop or change your treatment. You may also need other treatments. In some cases, it may be necessary to stop treatment with Temozolomide SUN.
* as you may have a small risk of other changes in blood cells, including leukaemia.
* if you have nausea (feeling sick) and/or vomiting which are very common side effects of Temozolomide SUN (see section 4), your doctor may prescribe you a medicine (an anti-emetic) to help prevent vomiting.

If you vomit frequently before or during treatment, ask your doctor about the best time to take Temozolomide SUN until the vomiting is under control. If you vomit after taking your dose, do not take a second dose on the same day.

* if you develop fever or symptoms of an infection contact your doctor immediately.
* if you are older than 70 years of age, you might be more prone to infection, bruising or bleeding.
* if you have liver or kidney problems, your dose of Temozolomide SUN may need to be adjusted.

**Children and adolescents**

Do not give this medicine to children under the age of 3 years because it has not been studied.There is limited information in patients over 3 years of age who have taken Temozolomide SUN.

**Other medicines and Temozolomide SUN**

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

**Pregnancy, breast-feeding and fertility**

If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. This is because you must not be treated with Temozolomide SUN during pregnancy unless clearly indicated by your doctor.

Effective contraceptive precautions must be taken by female patients who are able to become pregnant during treatment with Temozolomide SUN, and for at least 6 months following completion of treatment.

You should stop breast-feeding while receiving treatment with Temozolomide SUN.

**Male fertility**

Temozolomide SUN may cause permanent infertility. Male patients should use effective contraception and not father a child for at least 3 months after stopping treatment. It is recommended to seek advice on conservation of sperm prior to treatment.

**Driving and using machines**

Temozolomide SUN may make you feel tired or sleepy. In this case, do not drive or use any tools or machines or cycle until you see how this medicine affects you (see section 4).

**Temozolomide SUN contains lactose**

Temozolomide SUN contains lactose (a kind of sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.

1. **How to take Temozolomide SUN**

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

Dosage and duration of treatment

Your doctor will work out your dose of Temozolomide SUN. This is based on your size (height and weight) and whether you have a recurrent tumour and have had chemotherapy treatment in the past.

You may be given other medicines (anti-emetics) to take before and/or after taking Temozolomide SUN to prevent or control nausea and vomiting.

*Patients with newly-diagnosed glioblastoma multiforme*

If you are a newly-diagnosed patient, treatment will occur in two phases:

- treatment together with radiotherapy (concomitant phase) first

- followed by treatment with Temozolomide SUN only (monotherapy phase).

During the concomitant phase, your doctor will start Temozolomide SUN at a dose of 75 mg/m2 (usual dose). You will take this dose every day for 42 to 49 days in combination with radiotherapy. The Temozolomide SUN dose may be delayed or stopped, depending on your blood counts and how you tolerate your medicine during the concomitant phase.

Once the radiotherapy is completed, you will have no treatment for 4 weeks. This will give your body a chance to recover.

Then, you will start the monotherapy phase.

During the monotherapy phase, the dose and way you take Temozolomide SUN can vary. Your doctor will work out your exact dose. There may be up to 6 treatment periods (cycles). Each one lasts 28 days. The first dose will be 150 mg/m2. You will take your new dose of Temozolomide SUN once daily for the first 5 days (“dosing days”) of each cycle. Then you will have 23 days without Temozolomide SUN. This adds up to a 28-day treatment cycle.

After day 28, the next cycle will begin. You will again take Temozolomide SUN once daily for 5 days followed by 23 days without Temozolomide SUN. The Temozolomide SUN dose may be adjusted, delayed or stopped depending on your blood counts and how you tolerate your medicine during each treatment cycle.

*Patients with tumours that have returned or worsened (malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma) taking Temozolomide SUN only*

A treatment cycle with Temozolomide SUN lasts 28 days.

You will take Temozolomide SUN only once daily for the first 5 days. This daily dose depends on whether or not you have received chemotherapy before.

If you have not been previously treated with chemotherapy, your first dose of Temozolomide SUN will be 200 mg/m2 once daily for the first 5 days. If you have been previously treated with chemotherapy, your first dose of Temozolomide SUN will be 150 mg/m2 once daily for the first 5 days. Then, you will have 23 days without Temozolomide SUN. This adds up to a 28-day treatment cycle.

After day 28, the next cycle will begin. You will again receive Temozolomide SUN once daily for 5 days, followed by 23 days without Temozolomide SUN.

Before each new treatment cycle, your blood will be tested to see if the Temozolomide SUN dose needs to be adjusted. Depending on your blood test results, your doctor may adjust your dose for the next cycle.

How to take Temozolomide SUN

Take your prescribed dose of Temozolomide SUN once a day, preferably at the same time each day.

Take the capsules on an empty stomach; for example, at least one hour before you plan to eat breakfast. Swallow the capsule(s) whole with a glass of water. Do not open, crush or chew the capsules. If a capsule is damaged, avoid contact of the powder with your skin, eyes or nose. If you accidentally get some in your eyes or nose, flush the area with water.



Depending on the prescribed dose, you may have to take more than one capsule at the same time. You may have to take different strengths to make up the dose. The marking on the capsule is different for each strength (see table below).

|  |  |
| --- | --- |
| Strength | Imprint |
| Temozolomide SUN **5 mg** hard capsules | 890 & 5 mg |
| Temozolomide SUN **20 mg** hard capsules | 891 & 20 mg |
| Temozolomide SUN **100 mg** hard capsules | 892 & 100 mg |
| Temozolomide SUN **140 mg** hard capsules | 929 & 140 mg |
| Temozolomide SUN **180 mg** hard capsules | 930 & 180 mg |
| Temozolomide SUN **250 mg** hard capsules | 893 & 250 mg |

You should make sure you fully understand and remember the following:

* the number of capsules you need to take every dosing day. Ask your doctor or pharmacist to write it down (including the marking)
* which days are your dosing days.

Review the dose with your doctor each time you start a new cycle, since it may be different from the last cycle.

Always take Temozolomide SUN exactly as your doctor has told you. It is very important to check with your doctor or pharmacist if you are not sure. Making a mistake in how you take this medicine may have serious health consequences.

**If you take more Temozolomide SUN than you should**

If you accidentally take more Temozolomide SUN capsules than you were told to, contact your doctor, pharmacist or nurse immediately.

**If you forget to take Temozolomide SUN**

Take the missed dose as soon as possible during the same day. If a full day has gone by, check with your doctor. Do not take a double dose to make up for a forgotten dose, unless your doctor tells you to do so.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

1. **Possible side effects**

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Contact your doctor **immediately** if you have any of the following:

- a severe allergic (hypersensitive) reaction (hives, wheezing or other breathing difficulty)

- uncontrolled bleeding

- seizures (convulsions)

- fever

- chills

- severe headache that does not go away.

Temozolomide SUN treatment can cause a reduction in certain kinds of blood cells. This may cause you to have increased bruising or bleeding, anaemia (a shortage of red blood cells), fever, and reduced resistance to infections. The reduction in blood cell counts is usually short-lived. In some cases, it may be prolonged and may lead to a very severe form of anaemia (aplastic anaemia). Your doctor will monitor your blood regularly for any changes, and will decide if any specific treatment is needed. In some cases, your Temozolomide SUN dose will be reduced or treatment stopped.

Other side effects that have been reported are listed below:

**Very common side effects (may affect more than 1 in 10 people) are:**

* loss of appetite, difficulty speaking, headache
* vomiting, nausea, diarrhoea, constipation
* rash, hair loss
* tiredness.

**Common side effects (may affect up to 1 in 10 people) are:**

* infections, oral infections, wound infections
* reduced number of blood cells (neutropenia, lymphopenia, thrombocytopenia)
* allergic reaction
* increased blood sugar
* memory impairment, depression, anxiety, confusion, inability to fall asleep or stay asleep
* impaired coordination and balance
* difficulty concentrating, change in mental status or alertness, forgetfulness
* dizziness, impaired sensations, tingling sensations, shaking, abnormal taste
* partial loss of vision, abnormal vision, double vision, dry or painful eyes
* deafness, ringing in the ears, earache
* blood clot in lung or legs, high blood pressure
* pneumonia, shortness of breath, bronchitis, cough, inflammation of your sinuses
* stomach or abdominal pain, upset stomach/heartburn, difficulty swallowing
* dry skin, itching
* muscle damage, muscle weakness, muscle aches and pain
* painful joint, back pain
* frequent urination, difficulty withholding your urine
* fever, flu-like symptoms, pain, feeling unwell, a cold or the flu
* fluid retention, swollen legs
* liver enzyme elevations
* loss of weight, weight gain
* radiation injury.

**Uncommon side effects (may affect up to 1 in 100 people) are:**

* brain infections (meningoencephalitis herpetic) including fatal cases
* new or reactivated cytomegalovirus infections
* reactivated hepatitis B virus infections
* secondary cancers including leukaemia
* reduced blood cell counts (pancytopenia, anaemia, leukopenia)
* red spots under the skin
* diabetes insipidus (symptoms include increased urination and feeling thirsty), low potassium level in the blood
* mood swings, hallucination
* partial paralysis, change in your sense of smell
* hearing impairment, infection of the middle ear
* palpitations (when you can feel your heart beat), hot flushes
* swollen stomach, difficulty controlling your bowel movements, haemorrhoids, dry mouth
* hepatitis and injury to the liver (including fatal liver failure), cholestasis, increased bilirubin
* blisters on body or in mouth, skin peeling, skin eruption, painful reddening of the skin, severe rash with skin swelling (including palms and soles)
* increased sensitivity to sunlight, urticaria (hives), increased sweating, change in skin colour
* difficulty in urinating
* vaginal bleeding, vaginal irritation, absent or heavy menstrual periods, breast pain, sexual impotence
* shivering, face swelling, discolouration of the tongue, thirst, tooth disorder.

**Reporting of side effects**

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

1. **How to store Temozolomide SUN**

Keep this medicine out of the sight and reach of children, preferably in a locked cupboard. Accidental ingestion can be lethal for children.

Do not use this medicine after the expiry date which is stated on the label and carton. The expiry date refers to the last day of that month.

Do not store above 25°C.

Tell your pharmacist if you notice any change in the appearance of the capsules.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

1. **Contents of the pack and other information**

**What Temozolomide SUN contains**

- The active substance is temozolomide.

*Temozolomide SUN 5 mg hard capsules*: Each hard capsule contains 5 mg temozolomide.

*Temozolomide SUN 20 mg hard capsules*: Each hard capsule contains 20 mg temozolomide.

*Temozolomide SUN 100 mg hard capsules*: Each hard capsule contains 100 mg temozolomide.

*Temozolomide SUN 140 mg hard capsules*: Each hard capsule contains 140 mg temozolomide.

*Temozolomide SUN 180 mg hard capsules*: Each hard capsule contains 180 mg temozolomide.

*Temozolomide SUN 250 mg hard capsules*: Each hard capsule contains 250 mg temozolomide.

- The other ingredients are:

*capsule content:* lactose, sodium starch glycolate (Type B), tartaric acid, stearic acid (see section 2 "Temozolomide SUN contains lactose")

*capsule shell*: gelatin, titanium dioxide (E171), sodium laurilsulfate

*printing ink:*

*Temozolomide SUN 5 mg hard capsules*: shellac, propylene glycol, yellow iron oxide (E172), blue #1/Brilliant Blue FCF Aluminium Lake (E133).

*Temozolomide SUN 20 mg hard capsules*:shellac, propylene glycol, yellow iron oxide (E172).

*Temozolomide SUN 100 mg hard capsules*: shellac, propylene glycol, red iron oxide (E172), yellow iron oxide (E172), titanium dioxide (E171).

*Temozolomide SUN 140 mg hard capsules*: shellac, propylene glycol, titanium dioxide (E171), blue #1/Brilliant Blue FCF Aluminium Lake (E133).

*Temozolomide SUN 180 mg hard capsules*: shellac, propylene glycol, red iron oxide (E172).

*Temozolomide SUN 250 mg hard capsules*: shellac, propylene glycol, black iron oxide (E172).

**What Temozolomide SUN looks like and contents of the pack**

5 mg hard capsules

Temozolomide SUN 5 mg hard capsules have a white opaque body and cap, imprinted in green ink. The cap is imprinted with ‘890’. The body is imprinted with ‘5 mg’ and two stripes.

20 mg hard capsules

Temozolomide SUN 20 mg hard capsules have a white opaque body and cap, imprinted in yellow ink. The cap is imprinted with ‘891’. The body is imprinted with ’20 mg’ and two stripes.

100 mg hard capsules

Temozolomide SUN 100 mg hard capsules have a white opaque body and cap, imprinted in pink ink. The cap is imprinted with ‘892’. The body is imprinted with ‘100 mg’ and two stripes.

140 mg hard capsules

Temozolomide SUN 140 mg hard capsules have a white opaque body and cap, imprinted in blue ink. The cap is imprinted with ‘929’. The body is imprinted with ‘140 mg’ and two stripes.

180 mg hard capsules

Temozolomide SUN 180 mg hard capsules have a white opaque body and cap, imprinted in red ink. The cap is imprinted with ‘930’. The body is imprinted with ‘180 mg’ and two stripes.

250 mg hard capsules

Temozolomide SUN 250 mg hard capsules have a white opaque body and cap, imprinted in black ink. The cap is imprinted with ‘893’. The body is imprinted with ‘250 mg’ and two stripes.

The hard capsules are available in blister packs containing 5 capsules. For the 20 capsules packs, 4 blisters of 5 capsules will be included in a carton.

Not all pack sizes may be marketed.

**Marketing Authorisation Holder and Manufacturer**

Sun Pharmaceutical Industries Europe B.V.

Polarisavenue 87

2132 JH Hoofddorp

The Netherlands

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.

**België/Belgique/Belgien/България/Česká republika/**

**Danmark/Eesti/Ελλάδα/Hrvatska/Ireland/Ísland/**

**Κύπρος/Latvija/Lietuva/Luxembourg/Luxemburg/Magyarország/**

**Malta/Nederland/Norge/Österreich/Portugal/**

**Slovenija/Slovenská republika/Suomi/Finland/Sverige**

Sun Pharmaceutical Industries Europe B.V.

Polarisavenue 87

2132 JH Hoofddorp

Nederland/Pays-Bas/Niederlande/Нидерландия/Nizozemsko/

Nederlandene/Holland/Ολλανδία/Nizozemska/The Netherlands/Holland/

Ολλανδία/Nīderlande/Nyderlandai/Pays-Bas/Niederlande/Hollandia/

L-Olanda/Nederland/Nederland/Niederlande/Países Baixos/

Nizozemska/Holandsko/Alankomaat/Nederländerna/Nederländerna

Tel./тел./tlf./τηλ./Sími/τηλ./Tlf./Puh./

 +31 (0)23 568 5501

**Deutschland**

Sun Pharmaceuticals Germany GmbH

Hemmelrather Weg 201

51377 Leverkusen

Deutschland

tel. +49 214 403 990

**España**

Sun Pharma Laboratorios, S.L.

Rambla de Catalunya 53-55

08007 Barcelona

España

tel. +34 93 342 78 90

**France**

Sun Pharma France

31 Rue des Poissonniers

92200 Neuilly-Sur-Seine

France

Tel. +33 1 41 44 44 50

**Italia**

Sun Pharma Italia Srl

Viale Giulio Richard, 3

20143 Milano

Italia

tel. +39 02 33 49 07 93

**Polska**

Ranbaxy (Poland) Sp. z o.o.

ul. Idzikowskiego 16

00-710 Warszawa

Polska

Tel. +48 22 642 07 75

**România**

Terapia S.A.

Str. Fabricii nr 124

Cluj-Napoca, Judeţul Cluj

România

Tel. +40 (264) 501 500

**United Kingdom (Northern Ireland)**

Ranbaxy UK Ltd

a Sun Pharma Company

Millington Road 11

Hyde Park, Hayes 3

5th Floor

UB3 4AZ HAYES

United Kingdom

Tel. +44 (0) 208 848 8688

**This leaflet was last revised in**

**Other sources of information**

Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu/.